Answers are grounded in this paper and cite their sources.
Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4 receptor α subunit, inhibits IL-4 and IL-13 signaling and has become a mainstay treatment for moderate-to-severe atopic dermatitis (AD).1 By suppressing type 2 inflammation, dupilumab improves pruritus, sleep, and skin barrier integrity.2,3 However, a growing body of literature describes “paradoxical” inflammatory eruptions emerging during IL-4/IL-13 blockade, including psoriasis and psoriasiform dermatitis.4,5 This phenomenon is thought to reflect immune repolarization toward T helper (Th) 17/IL-23 pathways after suppression of Th2 inflammation, representing a “phenotype switch” rather than a true “paradoxical” eruption.
No takes yet. Share an insight, caveat, or question.
Craver et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: